BLA 103691 · Smith and Nephew
Regranex
Becaplermin · Topical · Human Platelet-derived Growth Factor
NovelLast checked: Nov 20, 2026Latest source record: Aug 26, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 16, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
23
5 Phase 3, 2 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 8, 2026.
REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use: The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies ( 14.2 ) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology ( 13.2 ) ]. REGRANEX is not intended to be used in wounds that close by primary intention. REGRANEX is a human platelet-derived growth factor indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX is indicated as an adjunct to, and not a substitute for, good ulcer care practices. ( 1 ) Limitations of Use: The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers. ( 1 ) The effects of REGRANEX on exposed joints, tendons, ligaments, and bone have not been established in humans. ( 1 ) REGRANEX is not intended to be used in wounds that close by primary intention. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 28, 2018 Supplement 5134 · Efficacy LabelMedication GuideLetter
- May 13, 2005 Supplement 5015 · Efficacy LabelReviewLetter
- Dec 16, 1997 Original approval · Type 1 - New Molecular Entity ReviewLabelOther Important Information from FDA
1 products under this application
- REGRANEX · BECAPLERMIN 100UG/G · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Becaplermin" as an intervention, any sponsor and status, largest first.
- A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot UlcerPivotal-lookingCompleted
AdociaIndustry
NCT02236793 · 252 participants · Start Dec 2014 · Primary completion Aug 2016
Drug: BioChaperone PDGF-BB · For: Diabetic Foot Ulcer
Sites: Hyderabad, India; Mumbai, India; Chennai, India · 32 sites in all
- Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot UlcerPivotal-lookingCompleted
Virchow GroupIndustry
NCT01098357 · 192 participants · Start Jun 2010 · Primary completion Feb 2011
Drug: Biochaperone PDGF-BB Low dose; Biochaperone PDGF-BB High dose and 2 more · For: Diabetic Foot Ulcers
Sites: Rajkot, India; Bangalore, India; Kochi, India · 7 sites in all
- Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level GainPivotal-lookingCompleted
University of MichiganAcademic, hospital or other
NCT01530126 · 180 participants · Start Jan 2000 · Primary completion Jan 2005
Drug: B-TCP + 0.3 mg/ml rhPDGF-BB in buffer; B-TCP + 1.0 mg/ml rhPDGF-BB in buffer and 1 more · For: Periodontitis
Sites: Ann Arbor, Michigan
- Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical BurnsStatus unknown
American Scitech InternationalAcademic, hospital or other
NCT00812513 · 120 participants (planned) · Start Jul 2011 · Primary completion Apr 2012
Drug: R-Pdf/Gbb 0.01% gel · For: Burns; Electric Burns
Sites: Livingston, New Jersey
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDPivotal-lookingTerminated
Ophthotech CorporationIndustry
NCT02214628 · 101 participants · Start Jul 2014 · Primary completion Dec 2016
Drug: Fovista® (anti-PDGF BB) plus anti-VEGF · For: Age-related Macular Degeneration
Sites: Phoenix, Arizona; Beverly Hills, California; Sacramento, California · 13 sites in all
- Phase II Study of the Effects of rhPDGF-BB Injection on Lateral EpicondylitisPivotal-lookingCompleted
BioMimetic TherapeuticsIndustry
NCT01746420 · 100 participants · Start Dec 12, 2012 · Primary completion Oct 21, 2014
Drug: rhPDGF-BB Injection; Placebo · For: Lateral Epicondylitis
Sites: Phoenix, Arizona; Tucson, Arizona; Jonesboro, Arkansas · 6 sites in all
- A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEXPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00034788 · 84 participants · Start Dec 2000
Drug: Becaplermin · For: Foot Ulcer; Diabetic Foot; Skin Ulcer and 1 more
- Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound HealingPivotal-lookingStatus unknown
McMaster UniversityAcademic, hospital or other
NCT02845466 · 80 participants (planned) · Start Aug 2018 · Primary completion Sep 2020
Drug: Becaplermin · For: Venous Ulcer; Foot Ulcer, Diabetic
Sites: Hamilton, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- abdominal pain lower1
- ammonia increased1
- ascites1
- blood glucose increased1
- hepatic cirrhosis1
- hepatic encephalopathy1
- increased tendency to bruise1
- international normalised ratio increased1
- iron deficiency anaemia1
- lymphoma1
- pancytopenia1
- pleural effusion1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Regranex (Becaplermin)
2024 spending
$1.9M
Beneficiaries
794
1,077 claims
Per beneficiary
$2,359
$92.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,677,047 |
| 2021 | $2,997,028 |
| 2022 | $7,244,933 |
| 2023 | $8,327,758 |
| 2024 | $1,872,885 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O, Persson U, Willis M, et al. · Pharmacoeconomics 2001 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ · Am J Surg 1998 · Clinical Trial, Randomized Controlled Trial
- Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
Smiell JM · Am J Surg 1998 · Clinical Trial, Research Support, Non-U.S. Gov't
- Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
Niezgoda JA, Van Gils CC, Frykberg RG, et al. · Adv Skin Wound Care 2005 · Clinical Trial, Multicenter Study
- Topical becaplermin improves outcomes in work related fingertip injuries.
Freedman BM, Oplinger EH, Freedman IS · J Trauma 2005 · Clinical Trial
- Cost Effectiveness of Becaplermin Gel on Wound Closure for the Treatment of Pressure Injuries.
Gilligan AM, Waycaster CR, Milne CT · Wounds 2018 · Randomized Controlled Trial
Sponsor: Smith and Nephew
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.